Active Substance: Pseudoephedrine HCl, Triprolidine HCl.
Overview
Welcome to Dwaey, specifically on TRIFED page.
This medicine contains an important and useful components, as it consists of
Pseudoephedrine HCl, Triprolidine HClis available in the market in concentration
Pseudoephedrine + Triprolidine
Severe hepatic impairment. Moderate to severe renal impairment. DM, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, hypertension, heart disease. May affect ability to drive or operate machinery. Pregnancy and lactation.
Pneumonia, Pharyngitis, Allergic rhinitis, Upper respiratory tract, Dry cough, Tracheolaryngitis
Concurrent use or within 2 wk of stopping MAOIs. Severe hypertension or coronary artery disease.
Dry mouth, nose and throat; skin rashes, tachycardia, drowsiness, sleep disturbances, urinary retention. Rarely, hallucinations.
3
Triprolidine hydrochloride is a potent competitive histamine H1-receptor antagonist with antimuscarinic and mild sedative properties. Pseudoephedrine, an alpha- and beta-adrenergic receptor agonist, mediates vasoconstriction via direct stimulation of alpha-adrenergic receptors of the respiratory mucosa.
Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine. Potentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.
Information not available